We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
+6.09%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$722M
AUM Growth
+$48.2M
Cap. Flow
+$7.56M
Cap. Flow %
1.05%
Top 10 Hldgs %
54.91%
Holding
52
New
15
Increased
11
Reduced
7
Closed
14

Top Buys

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$35.7M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$25.8M
3
LRMR icon
Larimar Therapeutics
LRMR
+$24.8M
4
UTHR icon
United Therapeutics
UTHR
+$18.6M
5
VYGR icon
Voyager Therapeutics
VYGR
+$14.4M

Top Sells

Rank Stock Value
1
ARNA
Arena Pharmaceuticals Inc
ARNA
+$43.1M
2
ZGNX
Zogenix, Inc.
ZGNX
+$39.2M
3
PBYI icon
Puma Biotechnology
PBYI
+$34M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$33.2M
5
AIMT
Aimmune Therapeutics
AIMT
+$28.7M

Sector Composition

Rank Sector Weight
1 Healthcare 80.54%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBT
26
PUT
DELISTED
Global Blood Therapeutics, Inc.
GBT
$9.04M 1.25%
200,000
+194,300
+3,409% +$8.85M
ACHN
27
DELISTED
Achillion Pharmaceuticals
ACHN
$8.46M 1.17%
2,988,716
-711,284
-19% -$2.42M
CTIC
28
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$7.65M 1.06%
1,537,020
-150,000
-9% -$656K
SRRA
29
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$6.75M 0.94%
57,023
-20,755
-27% -$2.08M
XLRN
30
CALL
DELISTED
Acceleron Pharma
XLRN
$5.24M 0.73%
+107,900
New +$3.93M
AMRN
31
CALL
Amarin Corp
AMRN
$299M
$4.93M 0.68%
79,810
+25,000
+46% +$1.55M
ACOR
32
CALL
DELISTED
Acorda Therapeutics
ACOR
$4.19M 0.58%
1,216
+1,058
+670% +$3.24M
AMRN
33
Amarin Corp
AMRN
$299M
$3.27M 0.45%
52,841
– –
CGEN icon
34
Compugen
CGEN
$222M
$2.51M 0.35%
+759,494
New +$2.86M
CLDX icon
35
Celldex Therapeutics
CLDX
$2.99B
$405K 0.06%
+53,632
New +$717K
STRM
36
DELISTED
Streamline Health Solutions
STRM
$183K 0.03%
8,676
– –
NVLN
37
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$9K ﹤0.01%
+2,500
New +$10K
CPRX
38
DELISTED
Catalyst Pharmaceutical
CPRX
– –
-2,695,742
Closed -$6.44M
NBIX icon
39
Neurocrine Biosciences
NBIX
$16.8B
– –
-400,000
Closed -$33.2M
PBYI icon
40
Puma Biotechnology
PBYI
$404M
– –
-500,000
Closed -$34M
PRTA icon
41
CALL
Prothena Corp
PRTA
$425M
– –
-500,000
Closed -$18.4M
PTCT icon
42
CALL
PTC Therapeutics
PTCT
$5.68B
– –
-200,000
Closed -$5.41M
VNDA icon
43
Vanda Pharmaceuticals
VNDA
$307M
– –
-309,800
Closed -$5.22M
YARW
44
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
– –
-14
Closed -$1.95M
LUMO
45
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-25,944
Closed -$1.69M
ACOR
46
PUT
DELISTED
Acorda Therapeutics
ACOR
– –
-1,667
Closed -$4.73M
ATRS
47
DELISTED
Antares Pharma, Inc.
ATRS
– –
-500,000
Closed -$1.1M
ARNA
48
CALL
DELISTED
Arena Pharmaceuticals Inc
ARNA
– –
-15,300
Closed -$604K
AIMT
49
DELISTED
Aimmune Therapeutics
AIMT
– –
-900,579
Closed -$28.7M
ECYT
50
DELISTED
Endocyte, Inc. Common Stock
ECYT
– –
-1,491,500
Closed -$13.6M
1
2
3

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q2 2018 Portfolio in Review

As of Q2 2018, Great Point Partners held 52 positions worth $722M, up 7.2% from $673M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

Great Point Partners's Q2 2018 filing shows 15 new, 11 increased, 7 reduced and 14 closed positions. Its largest new stake was Acadia Pharmaceuticals: 2,000,000 shares worth $30.5M. The largest sale was Arena Pharmaceuticals Inc, an estimated $43.1M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 84% a quarter earlier.

  • Great Point Partners's largest Q2 2018 buy was Acadia Pharmaceuticals: 2,000,000 shares worth $30.5M.
  • Great Point Partners added most to Acceleron Pharma in Q2 2018, an estimated $10.8M increase.
  • Great Point Partners's biggest Q2 2018 reduction was Arena Pharmaceuticals Inc, cutting an estimated $43.1M.
  • Great Point Partners fully exited Zogenix, Inc. in Q2 2018, selling an estimated $39.2M.
  • Great Point Partners's ten largest holdings make up 55% of its $722M portfolio in Q2 2018.
  • Great Point Partners opened 15 new positions and closed 14 in Q2 2018.
  • Great Point Partners's portfolio value rose 7.2% quarter-over-quarter to $722M.

Based on Great Point Partners's 13F filing for Q2 2018, filed 14 Aug 2018.